1. Home
  2. Companies
  3. MSB
  4. Announcements

Mesoblast (ASX:MSB)

ASX announcement history & article coverage

27
Total announcements
(in last 3 months)
5
With article
22
No article
Article coverage
19%
Transparent by design. Announcments by Mesoblast (ASX:MSB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.

27 Oct 2026 · 06:52 pm AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder
26 Oct 2026 · 07:24 pm AEST ASX Filing
Ceasing to be a substantial holder
Ceasing to be a substantial holder
22 Oct 2026 · 07:20 pm AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder
16 Oct 2026 · 10:15 am AEST ⚡ Price SensitiveMaterial ASX Filing
MSB Reports Increased Revenue and Improved Operating Spend
Mesoblast reports 44% Ryoncil revenue growth and 85% lower operating cash spend
Periodic Reports - Other
82
Mesoblast Ryoncil revenue jumps 44% as quarterly cash spend falls to US$2.3 million
14 Oct 2026 · 05:10 pm AEST ASX Filing
Notification of cessation of securities - MSB
Appendix 3H (Notification of cessation of securities)
14 Oct 2026 · 05:07 pm AEST ASX Filing
Notification regarding unquoted securities - MSB
Appendix 3G
14 Oct 2026 · 05:03 pm AEST ASX Filing
Application for quotation of securities - MSB
Appendix 2A
12 Oct 2026 · 04:23 pm AEST Material ASX Filing
Annual Report to Shareholders
Mesoblast reports FY2026 commercial growth as Ryoncil sales reach US$115.2 million
Annual ReportTop 20 shareholders
95
Mesoblast turns Ryoncil sales into a commercial launchpad, but profitability remains out of reach Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026 Wrap Market Wrap - Week 42 (12 Oct -> 16 Oct) 2026 Wrap
12 Oct 2026 · 04:13 pm AEST ASX Filing
Notice of Annual General Meeting and Proxy Form
Notice of Annual General MeetingProxy Form
12 Oct 2026 · 04:05 pm AEST ASX Filing
Appendix 4G and Corporate Governance Statement
Corporate GovernanceAppendix 4G
1 Oct 2026 · 06:49 pm AEST ASX Filing
Ceasing to be a substantial holder
Ceasing to be a substantial holder

30 Sept 2026 · 06:15 pm AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder
24 Sept 2026 · 09:52 am AEST ⚡ Price SensitiveMaterial ASX Filing
FDA Approves New Potency Assay for Commercial Ryoncil
Mesoblast receives FDA approval for new Ryoncil potency assay
Progress Report
78
Mesoblast wins FDA clearance for new Ryoncil potency test Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026 Wrap
23 Sept 2026 · 06:41 pm AEST ASX Filing
Ceasing to be a substantial holder
Ceasing to be a substantial holder

27 Aug 2026 · 08:39 am AEST ⚡ Price SensitiveMaterial ASX Filing
MSB Annual Financial Results and Operational Update
Mesoblast reports US$120M revenue with strong Ryoncil launch and Phase 3 trial completion
Web CastPreliminary Final Report
90
27 Aug 2026 · 08:33 am AEST ⚡ Price SensitiveMaterial ASX Filing
Annual Financial Results Presentation
Mesoblast reports US$115M revenue from RYONCIL launch, advances Phase 3 trials for chronic low back pain and heart failure
Company PresentationPreliminary Final Report
85
27 Aug 2026 · 08:21 am AEST ⚡ Price SensitiveMaterial ASX Filing
Preliminary Final Report including Appendix 4E
Mesoblast reports FY26 revenue growth to $120M on Ryoncil® sales, advances clinical pipeline, reduces net loss
Preliminary Final ReportFull Year Accounts
85
24 Aug 2026 · 05:50 pm AEST ASX Filing
Appendix 3Y - Philip Krause
Change of Director's Interest Notice
24 Aug 2026 · 05:40 pm AEST ASX Filing
Notification regarding unquoted securities - MSB
Appendix 3G
24 Aug 2026 · 05:38 pm AEST ASX Filing
Mesoblast 2026 Full Year Financial Results Webcast
Mesoblast to Host Webcast on FY 2026 Financial Results and Operational Highlights
Web Cast
40
17 Aug 2026 · 10:00 am AEST ⚡ Price SensitiveMaterial ASX Filing
Major Milestone Treatment Completed in P3 Trial for CLBP
Mesoblast completes patient treatment in pivotal Phase 3 trial for chronic low back pain
Progress Report
85
Mesoblast Completes Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026 Wrap
13 Aug 2026 · 05:52 pm AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder
7 Aug 2026 · 05:02 pm AEST ASX Filing
Ceasing to be a substantial holder
Ceasing to be a substantial holder
5 Aug 2026 · 06:29 pm AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder
3 Aug 2026 · 05:25 pm AEST ASX Filing
Ceasing to be a substantial holder
Ceasing to be a substantial holder

31 July 2026 · 05:06 pm AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder
30 July 2026 · 10:01 am AEST ⚡ Price SensitiveMaterial ASX Filing
Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast reports US$115M Ryoncil revenue first year post-FDA, expands indications and advances trials
Commitments Test Entity - Fourth Quarter Activity ReportCommitments Test Entity - Fourth Quarter Cashflow Report
85
Mesoblast Posts US$115M Ryoncil Revenue as Adult Trials and CAR Tech Advance Healthcare Wrap - Week 31 (27 July -> 31 July) 2026 Wrap